QCLS
Q/C Technologies Inc
NASDAQ · Pharmaceuticals
$3.94
+0.42 (+11.93%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 6.12M | 5.83M | 5.05M |
| Net Income | 729.3K | 769.8K | 662.9K |
| EPS | — | — | — |
| Profit Margin | 11.9% | 13.2% | 13.1% |
| Rev Growth | +22.0% | +12.4% | +6.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 2.12M | 1.91M | 1.81M |
| Total Equity | 7.11M | 7.32M | 6.47M |
| D/E Ratio | 0.30 | 0.26 | 0.28 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 1.12M | 1.08M | 875.0K |
| Free Cash Flow | 457.4K | 470.8K | 287.5K |